Financial results for the year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
EP Biocomposites Limited has submitted its audited annual financial results for FY25. Revenue from operations rose modestly to Rs 1,200.62 lakhs from Rs 1,143.92 lakhs in FY24, a growth of about 5%. Total expenses increased to Rs 1,069.80 lakhs, pushing profit before tax down to Rs 141.70 lakhs (from Rs 157.05 lakhs). Profit after tax declined to Rs 103.08 lakhs from Rs 114.97 lakhs, with basic EPS at Rs 6.13 versus Rs 6.84 earlier. The statutory auditor, S.P. Bhandare & Associates, issued an unqualified opinion stating the results give a true and fair view. The company also disclosed utilization of IPO proceeds of Rs 580.04 lakhs (raised via 5,04,000 shares at Rs 126 each), fully deployed toward lease deposits, loan repayment, working capital, and general corporate purposes as planned. Operating cash flow turned positive at Rs 163.33 lakhs versus a negative Rs 35.46 lakhs in FY24.
Revenue growth is tepid and bottom line slipped nearly 10%, so shareholders should watch cost control. However, a clean audit report, full deployment of IPO funds, and improved operating cash flow signal stable operations in the near term.